MSH|^~\&|MIC|ARH|||201912121432||ORU^R01|4128501|D|2.3|||AL|NE
PID|1||AB00008370|AB8289|LABTESTMALTESE^LUMED^||19901001|F||||||||||AB000707/19|9874837999
OBR|1|36706^MIC|00027830^19:U0000345R^MIC^19:U345^36706|500.1000^U^Urine Culture^^^630-4||201912121427|201912121427|||||||201912121427|Urine^^^Midstream urine|||||||||MB|F||||
OBX|1|CE|500.1000^U^Urine Culture^^^630-4^O:MRSA|1.1|MRSA^Staphylococcus aureus-MRSA||||||F|||201912121432
OBX|2|ST|500.1000^U^Urine Culture^^^630-4^P:COLCOUNT10|1.1|||||||F|||201912121432
OBX|3|ST|500.1000^U^Urine Culture^^^630-4^R:1000|1.1|>100|x 10*6 CFU/L||A|||F|||201912121432
OBX|4|ST|500.1000^U^Urine Culture^^^630-4|1.1|||||||F|||201912121432
NTE|1||Due to the rapid emergence of resistance, rifampin
NTE|2||monotherapy is not recommended.
NTE|3||
NTE|4||A copy of the result has been sent to Infection Control.
OBR|2||00027830^19:U0000345R^MIC^19:U345^36706|913.2500^P580^Vitek P580 Sensitivity^^^29576-6||201912121427|201912121427|||||||201912121427|Urine^^^Midstream urine|||||||||MB|F|U^1.1|||36706^MIC
OBX|1|ST|101.000^CFZ^Cefazolin^^76-0^76-0|||||R|||F|||201912121432
OBX|2|ST|101.100^CF^Cephalexin^^149-5^149-5|||||R|||F|||201912121432
OBX|3|ST|200.000^AUG^Amoxicillin/Clavulanate^^20-8^20-8|||||R|||F|||201912121432
OBX|4|ST|500.700^FD^Nitrofurantoin^^363-2^363-2|||||S|||F|||201912121432
OBX|5|ST|600.000^TS^Trimethoprim/sulfamethoxazole^^516-5^516-5|||||S|||F|||201912121432
OBX|6|ST|700.000^TE^Tetracycline^^496-0^496-0|||||S|||F|||201912121432
OBX|7|ST|700.100^DOX^Doxycycline^^225-3^225-3|||||S|||F|||201912121432
OBX|8|ST|800.000^VA^Vancomycin^^524-9^524-9|||||S|||F|||201912121432